Both in humans and animals, inhibiting IL-5 with monoclonal antibodies (mAbs) can decrease circulatory and bronchoalveolar eosinophilia caused by an allergic challenge or chronic disease [76–79]. Here, IL5 is linked to Increased total eosinophil count.